» Articles » PMID: 33500708

Beyond Glucose: Alternative Sources of Energy in Glioblastoma

Overview
Journal Theranostics
Date 2021 Jan 27
PMID 33500708
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. With a designation of WHO Grade IV, it is also the most lethal primary brain tumor with a median survival of just 15 months. This is often despite aggressive treatment that includes surgical resection, radiation therapy, and chemotherapy. Based on the poor outcomes and prevalence of the tumor, the demand for innovative therapies continues to represent a pressing issue for clinicians and researchers. In terms of therapies targeting metabolism, the prevalence of the Warburg effect has led to a focus on targeting glucose metabolism to halt tumor progression. While glucose is the dominant source of growth substrate in GBM, a number of unique metabolic pathways are exploited in GBM to meet the increased demand for replication and progression. In this review we aim to explore how metabolites from fatty acid oxidation, the urea cycle, the glutamate-glutamine cycle, and one-carbon metabolism are shunted toward energy producing pathways to meet the high energy demand in GBM. We will also explore how the process of autophagy provides a reservoir of nutrients to support viable tumor cells. By so doing, we aim to establish a foundation of implicated metabolic mechanisms supporting growth and tumorigenesis of GBM within the literature. With the sparse number of therapeutic interventions specifically targeting metabolic pathways in GBM, we hope that this review expands further insight into the development of novel treatment modalities.

Citing Articles

Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study.

Kiryttopoulos A, Evangeliou A, Katsanika I, Boukovinas I, Foroglou N, Zountsas B Front Nutr. 2025; 11:1489812.

PMID: 40041752 PMC: 11876051. DOI: 10.3389/fnut.2024.1489812.


Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes.

Basheer H, Salman N, Abdullah R, Elsalem L, Afarinkia K Transl Oncol. 2025; 53:102323.

PMID: 39970627 PMC: 11876755. DOI: 10.1016/j.tranon.2025.102323.


The promise of mitochondria in the treatment of glioblastoma: a brief review.

Liang Z, Zhao S, Liu Y, Cheng C Discov Oncol. 2025; 16(1):142.

PMID: 39924629 PMC: 11807951. DOI: 10.1007/s12672-025-01891-y.


The Role and Applied Value of Mitochondria in Glioma-Related Research.

Chen L, Zhang H, Shang C, Hong Y CNS Neurosci Ther. 2024; 30(12):e70121.

PMID: 39639571 PMC: 11621238. DOI: 10.1111/cns.70121.


Methionine deprivation inhibits glioma proliferation and EMT via the TP53TG1/miR-96-5p/STK17B ceRNA pathway.

Li J, Liu R, Hu H, Huang Y, Shi Y, Li H NPJ Precis Oncol. 2024; 8(1):270.

PMID: 39572759 PMC: 11582638. DOI: 10.1038/s41698-024-00763-y.


References
1.
Silberman A, Goldman O, Boukobza Assayag O, Jacob A, Rabinovich S, Adler L . Acid-Induced Downregulation of ASS1 Contributes to the Maintenance of Intracellular pH in Cancer. Cancer Res. 2018; 79(3):518-533. PMC: 6359973. DOI: 10.1158/0008-5472.CAN-18-1062. View

2.
DeBerardinis R, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S . Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007; 104(49):19345-50. PMC: 2148292. DOI: 10.1073/pnas.0709747104. View

3.
Hsu S, Kuo J, Chiang H, Wang H, Wang Y, Huang C . Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells. Oncotarget. 2018; 9(6):6883-6896. PMC: 5805523. DOI: 10.18632/oncotarget.23855. View

4.
Kesarwani P, Kant S, Prabhu A, Chinnaiyan P . The interplay between metabolic remodeling and immune regulation in glioblastoma. Neuro Oncol. 2017; 19(10):1308-1315. PMC: 5596164. DOI: 10.1093/neuonc/nox079. View

5.
Marquez J, Alonso F, Mates J, Segura J, Martin-Rufian M, Campos-Sandoval J . Glutamine Addiction In Gliomas. Neurochem Res. 2017; 42(6):1735-1746. DOI: 10.1007/s11064-017-2212-1. View